Mutations at human immunodeficiency virus type 1 reverse transcriptase tryptophan repeat motif attenuate the inhibitory effect of efavirenz on virus production (Q39914745)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Mutations at human immunodeficiency virus type 1 reverse transcriptase tryptophan repeat motif attenuate the inhibitory effect of efavirenz on virus production	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Mutations at human immunodeficiency virus type 1 reverse transcriptase tryptophan repeat motif attenuate the inhibitory effect of efavirenz on virus production (English)

1 reference

Europe PubMed Central

15 September 2017

1 reference

based on heuristic

inferred from title

author name string

Chien-Cheng Chiang

1

1 reference

Europe PubMed Central

15 September 2017

Shiu-Mei Wang

2

1 reference

Europe PubMed Central

15 September 2017

Ying-Tzu Tseng

3

1 reference

Europe PubMed Central

15 September 2017

Kuo-Jung Huang

4

1 reference

Europe PubMed Central

15 September 2017

Chin-Tien Wang

5

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

20 November 2008

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

383

1 reference

Europe PubMed Central

15 September 2017

2

1 reference

Europe PubMed Central

15 September 2017

261-270

1 reference

Europe PubMed Central

15 September 2017

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Human immunodeficiency virus type 1 nucleocapsid zn(2+) fingers are required for efficient reverse transcription, initial integration processes, and protection of newly synthesized viral DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Incorporation of pol into human immunodeficiency virus type 1 Gag virus-like particles occurs independently of the upstream Gag domain in Gag-pol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Generation of infectious virus particles by transient co-expression of human immunodeficiency virus type 1 gag mutants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

The virus-associated human immunodeficiency virus type 1 Gag-Pol carrying an active protease domain in the matrix region is severely defective both in autoprocessing and in trans processing of gag particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

A domain directly C-terminal to the major homology region of human immunodeficiency type 1 capsid protein plays a crucial role in directing both virus assembly and incorporation of Gag-Pol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Coding sequences upstream of the human immunodeficiency virus type 1 reverse transcriptase domain in Gag-Pol are not essential for incorporation of the Pr160(gag-pol) into virus particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Immunologic and proteolytic analysis of HIV-1 reverse transcriptase structure

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Folding of the multidomain human immunodeficiency virus type-I integrase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Rapid localization of Gag/GagPol complexes to detergent-resistant membrane during the assembly of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Characterization of ribosomal frameshifting in HIV-1 gag-pol expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Incorporation of human immunodeficiency virus type 1 reverse transcriptase into virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Genotypic predictors of human immunodeficiency virus type 1 drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Assembly and processing of human immunodeficiency virus Gag mutants containing a partial replacement of the matrix domain by the viral protease domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

Association of murine leukemia virus pol with virions, independent of Gag-Pol expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

based on heuristic

inferred from DOI database lookup

Incorporation of Pr160(gag-pol) into virus particles requires the presence of both the major homology region and adjacent C-terminal capsid sequences within the Gag-Pol polyprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

based on heuristic

inferred from DOI database lookup

The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and not as a Gag-Pol fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

based on heuristic

inferred from DOI database lookup

Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.027

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2008.10.027

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39914745&oldid=1878303213"